Mercer Global Advisors’s Teva Pharmaceuticals TEVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.47M | Buy |
87,742
+9,120
| +12% | +$153K | ﹤0.01% | 991 |
|
|
2025
Q1 | $1.21M | Sell |
78,622
-5,858
| -7% | -$90K | ﹤0.01% | 1043 |
|
|
2024
Q4 | $1.86M | Sell |
84,480
-7,756
| -8% | -$171K | ﹤0.01% | 853 |
|
|
2024
Q3 | $1.63M | Sell |
92,236
-5,403
| -6% | -$95.5K | ﹤0.01% | 832 |
|
|
2024
Q2 | $1.59M | Sell |
97,639
-252
| -0.3% | -$4.1K | ﹤0.01% | 785 |
|
|
2024
Q1 | $1.38M | Buy |
97,891
+26,293
| +37% | +$371K | ﹤0.01% | 833 |
|
|
2023
Q4 | $747K | Sell |
71,598
-48
| -0.1% | -$501 | ﹤0.01% | 1104 |
|
|
2023
Q3 | $731K | Sell |
71,646
-146
| -0.2% | -$1.49K | ﹤0.01% | 1074 |
|
|
2023
Q2 | $541K | Sell |
71,792
-111,165
| -61% | -$838K | ﹤0.01% | 1189 |
|
|
2023
Q1 | $1.62M | Buy |
182,957
+1,622
| +0.9% | +$14.4K | 0.01% | 744 |
|
|
2022
Q4 | $1.65M | Sell |
181,335
-90,696
| -33% | -$827K | 0.01% | 732 |
|
|
2022
Q3 | $2.2M | Buy |
272,031
+181,369
| +200% | +$1.46M | 0.01% | 606 |
|
|
2022
Q2 | $682K | Buy |
90,662
+54,692
| +152% | +$411K | ﹤0.01% | 999 |
|
|
2022
Q1 | $338K | Sell |
35,970
-4,554
| -11% | -$42.8K | ﹤0.01% | 1450 |
|
|
2021
Q4 | $325K | Buy |
40,524
+4,578
| +13% | +$36.7K | ﹤0.01% | 1424 |
|
|
2021
Q3 | $350K | Sell |
35,946
-8,861
| -20% | -$86.3K | ﹤0.01% | 1353 |
|
|
2021
Q2 | $444K | Buy |
44,807
+3,310
| +8% | +$32.8K | ﹤0.01% | 1201 |
|
|
2021
Q1 | $479K | Sell |
41,497
-37,577
| -48% | -$434K | ﹤0.01% | 1099 |
|
|
2020
Q4 | $763K | Buy |
79,074
+556
| +0.7% | +$5.37K | 0.01% | 708 |
|
|
2020
Q3 | $707K | Buy |
78,518
+56,839
| +262% | +$512K | 0.01% | 664 |
|
|
2020
Q2 | $267K | Buy |
21,679
+2,139
| +11% | +$26.3K | ﹤0.01% | 889 |
|
|
2020
Q1 | $175K | Buy |
+19,540
| New | +$175K | ﹤0.01% | 960 |
|